A carregar cotações...
Previsão
| Comprar |
0 |
| Manter |
1 |
| Vender |
0 |
Notícias Ir para o feed de notícias
Predictive Oncology approves increase to equity incentive plan and issuance of pre‑funded warrants
At the annual meeting, shareholders voted to increase the 2024 Equity Incentive Plan by 1,000,000 shares and to issue 14,903,393 common shares that will be issued upon exercise of pre‑funded warrants. The elections of directors Daniel E. Handley and Chuck Nuzum were confirmed and KPMG was appointed as independent auditors. Predictive Oncology also reported a significant net loss in Q3 2025, but said it has regained compliance with NASDAQ’s minimum stockholders’ equity requirement and is pursuing initiatives to enter the AI infrastructure market. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | junho de 2026 | YoY |
|---|---|---|
| Receitas | 2,82 mi | 123.699,49% |
| Ganho bruto | 176,69 mil | 1.440,23% |
| Ganho líquido | -15,08 mi | 758,24% |
| EBITDA | -3,52 mi | 129,57% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 79,5 mi |
Número de ações | 11,38 mi |
Máximo/mínimo de 52 semanas | € 28,65 - € 0,92 |
| Dividendos | Não |
Beta | 3,68 |
PER (PE Ratio) | -0,05 |
PEG (PEG Ratio) | 0,00 |
P/VC (PB Ratio) | 4,52 |
P/V (PS Ratio) | 27,31 |
Perfil da empresa
| Nome | Predictive Oncology |
| CEO | Christopher Miglino |
| Colaboradores | 14 |
